Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422994 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
A Phase 1 study of Restless Legs Syndrome, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT00422994 is a Phase 1 study of Restless Legs Syndrome that has completed, run by GlaxoSmithKline. The registered enrollment target is 48 participants, below the 93-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (48% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00422994, a Phase 1 study of Restless Legs Syndrome, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.
Conditions Studied
Interventions
- DRUG ropinirole dosing for up to 28 days
Study Locations (2)
Minnesota
- GSK Investigational Site - Minneapolis
Other
- GSK Investigational Site - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422994
The ClinicalTrials.gov registry entry for NCT00422994 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 93-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (48% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which ropinirole dosing for up to 28 days is the first listed.
NCT00422994 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Other.
Frequently Asked Questions
What is clinical trial NCT00422994 about?
NCT00422994 is a clinical study titled "A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole". This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.
What is the current status of trial NCT00422994?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2006-04. Estimated completion is 2006-12.
What conditions does trial NCT00422994 study?
This clinical trial studies the following conditions: Restless Legs Syndrome.
What interventions are being tested in trial NCT00422994?
The interventions under investigation include: ropinirole dosing for up to 28 days (DRUG).
Who is sponsoring clinical trial NCT00422994?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00422994 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers
COMPLETED · Phase 1
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.